Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review

Acta Neurologica Scandinavica

Volumn 130, Issue 2, 2014, Pages 59-72

  Malek, N ^a   Swallow, D ^a   Grosset, K A ^a   Anichtchik, O ^b,c   Spillantini, M ^b   Grosset, D G ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

Author keywords

Alpha synuclein; Biomarker; Lewy body; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER;

BODY FLUID; BRONCHUS; CEREBROSPINAL FLUID ANALYSIS; COLON MUCOSA; ENDOCRINE GLAND; GASTROINTESTINAL TRACT; HUMAN; LARYNX; LUNG PARENCHYMA; OLFACTORY EPITHELIUM; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM; REVIEW; SALIVARY GLAND; SCIATIC NERVE; SENSITIVITY AND SPECIFICITY; SKIN BIOPSY; SUBMANDIBULAR GLAND; SYMPATHETIC GANGLION; SYSTEMATIC REVIEW; UROGENITAL SYSTEM; VAGUS NERVE; METABOLISM;

ALPHA-SYNUCLEIN; BIOMARKERS; HUMANS; PARKINSON DISEASE;

EID: 84904744897     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12247     Document Type: Review

References (93)

1. Kiely AP, Asi YT, Kara E et al. alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol 2013;125:753-69.
2. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
3. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997;12:133-47.
4. Sinha N, Firbank M, O'Brien JT. Biomarkers in dementia with Lewy bodies: a review. Int J Geriatr Psychiatry 2012;27:443-53.
5. Ueda K, Fukushima H, Masliah E et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993;90:11282-6.
6. Campion D, Martin C, Heilig R et al. The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. Genomics 1995;26:254-7.
7. Beyer K, Ariza A. Alpha-synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol Neurobiol 2013;47:509-24.
8. Levitan K, Chereau D, Cohen SI et al. Conserved C-terminal charge exerts a profound influence on the aggregation rate of alpha-synuclein. J Mol Biol 2011;411:329-33.
9. Uversky VN. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem 2007;103:17-37.
10. Bernstein SL, Liu D, Wyttenbach T et al. Alpha-synuclein: stable compact and extended monomeric structures and pH dependence of dimer formation. J Am Soc Mass Spectrom 2004;15:1435-43.
11. Iwai A, Masliah E, Yoshimoto M et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995;14:467-75.
12. Uversky VN, Li J, Souillac P et al. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem 2002;277:11970-8.
13. Breydo L, Wu JW, Uversky VN. Alpha-synuclein misfolding and Parkinson's disease. Biochim Biophys Acta 2012;1822:261-85.
14. McLean PJ, Hyman BT. An alternatively spliced form of rodent alpha-synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in alpha-synuclein aggregation. Neurosci Lett 2002;323:219-23.
15. Bennett MC. The role of alpha-synuclein in neurodegenerative diseases. Pharmacol Ther 2005;105:311-31.
16. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-72.
17. Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord 2012;27:8-30.
18. Uversky VN, Eliezer D. Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci 2009;10:483-99.
19. Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
20. Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord 2003;18(Suppl 6):S2-12.
21. Nakai M, Fujita M, Waragai M et al. Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson's disease, in erythropoietic lineage. Biochem Biophys Res Commun 2007;358:104-10.
22. Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005;25:6016-24.
23. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998;95:6469-73.
24. Caviness JN. Presymptomatic Parkinson's disease: the Arizona experience. Parkinsonism Relat Disord 2012;18(Suppl 1):S203-6.
25. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396:67-72.
26. Klos KJ, Ahlskog JE, Josephs KA et al. Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology 2006;66:1100-2.
27. DelleDonne A, Klos KJ, Fujishiro H et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 2008;65:1074-80.
28. Beach TG, Adler CH, Sue LI et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119:689-702.
29. Michell AW, Luheshi LM, Barker RA. Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease. Neurosci Lett 2005;381:294-8.
30. Duda JE, Shah U, Arnold SE, Lee VM, Trojanowski JQ. The expression of alpha-, beta-, and gamma-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases. Exp Neurol 1999;160:515-22.
31. Beach TG, White CL 3rd, Hladik CL et al. Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol 2009;117:169-74.
32. Witt M, Bormann K, Gudziol V et al. Biopsies of olfactory epithelium in patients with Parkinson's disease. Mov Disord 2009;24:906-14.
33. Lebouvier T, Chaumette T, Damier P et al. Pathological lesions in colonic biopsies during Parkinson's disease. Gut 2008;57:1741-3.
34. Lebouvier T, Neunlist M, Bruley des Varannes S et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS ONE 2010;5:e12728.
35. Pouclet H, Lebouvier T, Coron E, Des Varannes SB, Neunlist M, Derkinderen P. A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson's disease. Neurogastroenterol Motil 2012;24:e202-5.
36. Pouclet H, Lebouvier T, Coron E et al. A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson's disease. Neurobiol Dis 2012;45:305-9.
37. Shannon KM, Keshavarzian A, Mutlu E et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 2012;27:709-15.
38. Cersosimo MG, Perandones C, Micheli FE et al. Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson's disease patients. Mov Disord 2011;26:188-90.
39. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol 2010;119:703-13.
40. Beach TG, Adler CH, Dugger BN et al. Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol 2013;72:130-6.
41. Mu L, Sobotka S, Chen J et al. Parkinson disease affects peripheral sensory nerves in the pharynx. J Neuropathol Exp Neurol 2013;72:614-23.
42. Iwanaga K, Wakabayashi K, Yoshimoto M et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 1999;52:1269-71.
43. Fujishiro H, Frigerio R, Burnett M et al. Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov Disord 2008;23:1085-92.
44. Orimo S, Uchihara T, Nakamura A et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 2008;131:642-50.
45. Orimo S, Uchihara T, Nakamura A et al. Cardiac sympathetic denervation in Parkinson's disease linked to SNCA duplication. Acta Neuropathol 2008;116:575-7.
46. Ghebremedhin E, Del Tredici K, Langston JW, Braak H. Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: an anatomical study. Acta Neuropathol 2009;118:777-84.
47. El-Agnaf OM, Salem SA, Paleologou KE et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006;20:419-25.
48. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm 2006;113:1435-9.
49. Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, Vives F. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment. Mov Disord 2010;25:489-93.
50. Li QX, Mok SS, Laughton KM et al. Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol 2007;204:583-8.
51. Foulds PG, Mitchell JD, Parker A et al. Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J 2011;25:4127-37.
52. Mata IF, Shi M, Agarwal P et al. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 2010;67:1350-6.
53. Li QX, Campbell BC, McLean CA et al. Platelet alpha- and gamma-synucleins in Parkinson's disease and normal control subjects. J Alzheimers Dis 2002;4:309-15.
54. Brighina L, Prigione A, Begni B et al. Lymphomonocyte alpha-synuclein levels in aging and in Parkinson disease. Neurobiol Aging 2010;31:884-5.
55. Pchelina SN, Emelyanov AK, Yakimovskii AF et al. Reduced content of alpha-synuclein in peripheral blood leukocytes of patients with LRRK2-associated Parkinson's disease. Bull Exp Biol Med 2011;150:679-81.
56. Gorostidi A, Bergareche A, Ruiz-Martinez J et al. Alphalpha-synuclein levels in blood plasma from LRRK2 mutation carriers. PLoS ONE 2012;7:e52312.
57. Papachroni KK, Ninkina N, Papapanagiotou A et al. Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 2007;101:749-56.
58. Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, Morozova-Roche LA. alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS ONE 2011;6:e18513.
59. Besong-Agbo D, Wolf E, Jessen F et al. Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 2013;80:169-75.
60. Smith LM, Schiess MC, Coffey MP, Klaver AC, Loeffler DA. alpha-Synuclein and anti-alpha-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls. PLoS ONE 2012;7:e52285.
61. Miller DW, Hague SM, Clarimon J et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004;62:1835-8.
62. Fuchs J, Tichopad A, Golub Y et al. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J 2008;22:1327-34.
63. Tan EK, Chai A, Teo YY et al. Alpha-synuclein haplotypes implicated in risk of Parkinson's disease. Neurology 2004;62:128-31.
64. Jakowec MW, Petzinger GM, Sastry S, Donaldson DM, McCormack A, Langston JW. The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls. Neurosci Lett 1998;253:13-6.
65. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10:230-40.
66. Mollenhauer B, Trautmann E, Taylor P et al. Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett 2013;532:44-8.
67. Tokuda T, Salem SA, Allsop D et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006;349:162-6.
68. Hong Z, Shi M, Chung KA et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133:713-26.
69. Shi M, Zabetian CP, Hancock AM et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett 2010;480:78-82.
70. Hall S, Ohrfelt A, Constantinescu R et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445-52.
71. Borghi R, Marchese R, Negro A et al. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 2000;287:65-7.
72. Ohrfelt A, Grognet P, Andreasen N et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 2009;450:332-5.
73. Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J Clin Neurol 2011;7:215-22.
74. Foulds PG, Yokota O, Thurston A et al. Post mortem cerebrospinal fluid alpha-synuclein levels are raised in multiple system atrophy and distinguish this from the other alpha-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiol Dis 2012;45:188-95.
75. Parnetti L, Chiasserini D, Bellomo G et al. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord 2011;26:1428-35.
76. Devic I, Hwang H, Edgar JS et al. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 2011;134:e178.
77. Rohn TT. Targeting alpha-synuclein for the treatment of Parkinson's disease. CNS Neurol Disord Drug Targets 2012;11:174-9.
78. Siderowf A, Jennings D, Eberly S et al. Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov Disord 2012;27:406-12.
79. Jellinger KA. Formation and development of Lewy pathology: a critical update. J Neurol 2009;256(Suppl 3):270-9.
80. Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med 2010;14:457-87.
81. Caviness JN, Adler CH, Hentz JG et al. Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disorders. Clin Neurophysiol 2011;122:2426-32.
82. Harrower TP, Michell AW, Barker RA. Lewy bodies in Parkinson's disease: protectors or perpetrators? Exp Neurol 2005;195:1-6.
83. Navarro-Otano J, Gelpi E, Mestres CA et al. Alpha-synuclein aggregates in epicardial fat tissue in living subjects without parkinsonism. Parkinsonism Relat Disord 2013;19:27-31; discussion 27.
84. Sunwoo MK, Hong JY, Choi J, Park HJ, Kim SH, Lee PH. alpha-Synuclein pathology is related to postoperative delirium in patients undergoing gastrectomy. Neurology 2013;80:810-3.
85. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F et al. Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?: a cohort study. Neurology 2007;68:2012-8.
86. Forno LS. Concentric hyaline intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. J Am Geriatr Soc 1969;17:557-75.
87. Beach TG, White CL, Hamilton RL et al. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol 2008;116:277-88.
88. Barbour R, Kling K, Anderson JP et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 2008;5:55-9.
89. Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C, Lee MK. Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. J Neurosci 2012;32:3301-5.
90. Emmanouilidou E, Melachroinou K, Roumeliotis T et al. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci 2010;30:6838-51.
91. Shi M, Bradner J, Hancock AM et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570-80.
92. Croisier E, MRes DE, Deprez M et al. Comparative study of commercially available anti-alpha-synuclein antibodies. Neuropathol Appl Neurobiol 2006;32:351-6.
93. McGhee DJ, Royle PL, Thompson PA, Wright DE, Zajicek JP, Counsell CE. A systematic review of biomarkers for disease progression in Parkinson's disease. BMC Neurol 2013;13:35.